《2019版乳腺癌HER2检测指南》 - Suppr

Suppr

超能文献

[Guideline for HER2 detection in breast cancer, the 2019 version].

出版信息

Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):169-175. doi: 10.3760/cma.j.issn.0529-5807.2019.03.001.

DOI:10.3760/cma.j.issn.0529-5807.2019.03.001

PMID:30831640

Abstract

摘要

相似文献

[Guideline for HER2 detection in breast cancer, the 2019 version].《2019版乳腺癌HER2检测指南》

Zhonghua Bing Li Xue Za Zhi. 2019 Mar 8;48(3):169-175. doi: 10.3760/cma.j.issn.0529-5807.2019.03.001.

HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.根据2013年美国临床肿瘤学会/美国病理学家学会实践指南，对HER2免疫组化结果不明确的乳腺癌进行HER2荧光原位杂交分类。

Breast Cancer Res Treat. 2016 Feb;155(3):457-62. doi: 10.1007/s10549-016-3717-z. Epub 2016 Feb 19.

Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.应用2013年美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）指南及原位杂交银增强法（SISH）技术进行乳腺癌人表皮生长因子受体2（HER2）检测，会使更多患者被选入抗HER2治疗。

Virchows Arch. 2016 Apr;468(4):417-23. doi: 10.1007/s00428-016-1903-3. Epub 2016 Jan 11.

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.2013年美国病理学家学会/美国临床肿瘤学会（CAP/ASCO）关于人表皮生长因子受体2（HER2）荧光原位杂交（FISH）检测的更新指南建议增加了HER2阳性和HER2不确定的乳腺癌病例；836例浸润性乳腺癌HER2 FISH结果的回顾性研究

Breast Cancer Res Treat. 2016 Jun;157(3):405-11. doi: 10.1007/s10549-016-3824-x. Epub 2016 May 14.

Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.老年乳腺癌患者的肿瘤生物学——对遵循指南分层生存的影响是什么？一项对5378例患者的回顾性多中心队列研究。

Breast. 2015 Jun;24(3):256-62. doi: 10.1016/j.breast.2015.02.029. Epub 2015 Mar 11.

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.人表皮生长因子受体2阳性早期女性乳腺癌的全身靶向治疗：对2014年安大略癌症护理全身治疗指南证据的系统评价

Curr Oncol. 2015 Mar;22(Suppl 1):S114-22. doi: 10.3747/co.22.2322.

[Short version of the guideline "Early Detection of Breast Cancer in Germany"].[德国乳腺癌早期检测指南简版]

Z Arztl Fortbild Qualitatssich. 2004 Aug;98(5):361-73.

Short version of the Guideline: Early Detection of Breast Cancer in Germany. An evidence-, consensus-, and outcome-based guideline according to the German Association of the Scientific Medical Societies (AWMF) and the German Agency for Quality in Medicine (AeZQ).《德国乳腺癌早期检测指南简版》。这是一份基于证据、共识和结果的指南，由德国科学医学协会联合会（AWMF）和德国医学质量机构（AeZQ）制定。

J Cancer Res Clin Oncol. 2004 Sep;130(9):527-36. doi: 10.1007/s00432-004-0558-7. Epub 2004 Jun 18.

New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）关于人表皮生长因子受体2（HER2）检测的新指南建议增加了原位杂交检测及HER2阳性乳腺癌的复检比例。

Virchows Arch. 2016 Feb;468(2):207-11. doi: 10.1007/s00428-015-1871-z. Epub 2015 Oct 31.

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.三种不同方法检测结直肠癌 EGFR、HER2、c-MYC 和 MET 变异的对比分析：基因拷贝数增益、扩增状态和 2013 年 ASCO/CAP 乳腺癌 HER2 检测指南标准。

J Transl Med. 2017 Aug 1;15(1):167. doi: 10.1186/s12967-017-1265-x.

引用本文的文献

Association between real-time shear wave elastography findings and HER-2 expression in breast cancer.乳腺癌实时剪切波弹性成像结果与HER-2表达之间的关联

Transl Cancer Res. 2025 Jul 30;14(7):4071-4079. doi: 10.21037/tcr-2024-2359. Epub 2025 Jul 25.

Clinicopathological observation and prognostic factors of invasive breast cancer with medullary in Xinjiang.新疆乳腺髓样浸润性癌的临床病理观察及预后因素

BMC Med Inform Decis Mak. 2025 Jul 3;25(1):246. doi: 10.1186/s12911-025-03089-2.

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.KN026联合多西他赛治疗HER2阳性乳腺癌的疗效和安全性：一项II期临床试验

Cancer Commun (Lond). 2025 Apr;45(4):476-485. doi: 10.1002/cac2.12662. Epub 2025 Jan 18.

Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.整合传统生物标志物和新兴预测指标以评估乳腺癌新辅助化疗疗效：Ki-67、CDK4、EGFR、肿瘤浸润淋巴细胞和循环肿瘤DNA的多因素分析

BMC Womens Health. 2024 Dec 30;24(1):674. doi: 10.1186/s12905-024-03486-1.

Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in China.乳腺癌中HER2荧光原位杂交检测的实验室间变异性：中国一项多中心能力验证环式研究的结果

Diagn Pathol. 2024 Dec 20;19(1):161. doi: 10.1186/s13000-024-01588-w.

Challenges and improvements in HER2 scoring and histologic evaluation: insights from a national proficiency testing scheme for breast cancer diagnosis in China.在中国乳腺癌诊断的全国能力验证计划中获得的 HER2 评分和组织学评估的挑战和改进：见解。

Breast Cancer Res. 2024 Sep 3;26(1):128. doi: 10.1186/s13058-024-01884-9.

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition).《人表皮生长因子受体2低表达乳腺癌临床诊疗共识（2022年版）》

J Natl Cancer Cent. 2023 Sep 29;3(4):266-272. doi: 10.1016/j.jncc.2023.09.002. eCollection 2023 Dec.

HER2-low breast cancer: insights on pathological testing.人表皮生长因子受体2低表达乳腺癌：病理检测见解

Transl Breast Cancer Res. 2023 Apr 30;4:15. doi: 10.21037/tbcr-23-15. eCollection 2023.

Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer.中国乳腺病理组织学和免疫组织化学诊断能力验证：国家乳腺癌单病种质量控制项目的一项初步工作结果。

BMC Cancer. 2024 Jan 2;24(1):23. doi: 10.1186/s12885-023-11777-3.

Prognostic impact of PTK6 expression in triple negative breast cancer.PTK6 表达对三阴性乳腺癌的预后影响。

BMC Womens Health. 2023 Nov 7;23(1):575. doi: 10.1186/s12905-023-02736-y.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验